Loading
NASDAQHealthcareBiotechnology
Latest quote
$36.90
+$2.72 · +7.96%
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Previous close
$36.90
+$2.72 · +7.96%
After-hours
$37.7901
+$0.8901 · +2.41%
Oct 9, 7:55 PM ET
Regular session · ET · Market data may be delayed.
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Day range
Current $36.90
52-week range
Current $36.90
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
32
Expensive
Sentiment
51
Mixed
Risk
51
Elevated Risk
Momentum
64
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Day range
Current $36.90
52-week range
Current $36.90
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 527K USD | 3.16M USD | — | — |
| Gross profit | — | −527K USD | −3.16M USD | — | — |
| Research and development | 117.67M USD | 65.3M USD | 48.96M USD | 36.17M USD | 34.79M USD |
| Selling, general, and administrative | 48.64M USD | 38.62M USD | 41.74M USD | 30.16M USD | 59.07M USD |
| Operating expenses | 166.31M USD | 103.39M USD | 90.7M USD | 66.33M USD | 93.85M USD |
| Interest income | 10.96M USD | 11.56M USD | 5.58M USD | 1.5M USD | — |
| Interest expense | 5.48M USD | 2.28M USD | 920K USD | 1.5M USD | 359K USD |
| Depreciation and amortization | — | 527K USD | 3.16M USD | 3.18M USD | 2.62M USD |
| Operating income | −166.31M USD | −103.92M USD | −93.87M USD | −66.33M USD | −93.85M USD |
| Net income | −183.79M USD | −108.68M USD | −95.73M USD | −56.8M USD | −93.04M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$67.45
82.79% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 29, 2022 | 1:15 | — | — |
Stock split | Mar 3, 2020 | 1:8 | — | — |
Effective Aug 29, 2022
1:15
Effective Mar 3, 2020
1:8
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
